Affinity Technologies has appointed J. Michael Edwards as Chief Financial Officer. Takeaway Points bioAffinity Technologies ...

Affinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

Affinity Technologies today announced it appointed J. Michael Edwards as chief financial officer in September.

CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a biotech firm engaged in developing noninvasive tests for early-stage cancer detection, has appointed J. Michael Edwards as its ...

Edwards will report directly to bioAffinity Technologies President and CEO Maria Zannes. "We are delighted to welcome Michael ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer ...

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael Edwards ...